Skip to content
BYO LUX
BYO LUXBe Your Own Luxury
All Treatments
Cosmetic

Restylane SHAYPE

High-G prime NASHA HD chin-shaping HA filler for skeletal lower-face support

Duration
20-40 min
Downtime
1-7 days
Sessions
通常1 sessions+必要時タッチアップ (9-18 monthsごと再評価)

About This Treatment

Restylane SHAYPE is a high-G prime hyaluronic acid filler built on Galderma’s NASHA HD technology and designed primarily for non-surgical correction of chin retrusion and lower-face skeletal support deficits. Compared with softer HA fillers, it is intended to provide stronger projection and structural support, allowing chin advancement, lower-face balance, and profile refinement with relatively small volumes.

Following approval in Canada in 2024, rollout in Brazil in 2025, and Galderma’s July 23, 2026 disclosure of a third approval in Thailand, it has become one of the more visible newer structural chin fillers in international injectables. Regional approval status remains uneven, so local market authorization must still be checked.

Mechanism of Action

A dense, high-elasticity cross-linked HA gel is placed supraperiosteally or in deep soft tissue to provide forward projection and support in the mental region. NASHA HD is designed for high G-prime and shape retention, helping maintain contour support in the dynamic lower face, although depth, plane, and volume control are critical in the anatomically tight chin area.

Indications

Sagging / contourGeneral indication (see detailed description)

Expected Results

Product-specific randomized trials have shown meaningful improvement in chin retrusion and high naturalness ratings by Week 12 after a single treatment. A 2026 comparator trial also supported effectiveness and favorable safety versus Juvéderm Volux, reinforcing its role as a high-support filler capable of strong projection with modest volumes. Most patients are assessed after one session with optional touch-up.

Clinical Evidence

Product-specific / peer-reviewed
Nikolis A, Humphrey S, Rivers JK, et al. (2024)
Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol
Clinical improvement was reported in this study (see original paper for details).
Product-specific / peer-reviewed
Nikolis A, Metelitsa A, Raco L, Safran T (2026)
Safety and Effectiveness of Two High-G' Soft Tissue Fillers for Chin Augmentation: A Prospective, Randomized, Comparator-Controlled, Evaluator-Blinded Trial. Aesthet Surg J
Clinical improvement was reported in this study (see original paper for details).
Indirect / ingredient class
Go BC, Frost AS, Friedman O (2023)
Using Injectable Fillers for Chin and Jawline Rejuvenation. World J Otorhinolaryngol Head Neck Surg
Clinical improvement was reported in this study (see original paper for details).
Manufacturer material
Galderma (2026)
Galderma reports record first half 2026 net sales of 3.134 billion USD and 24.6% year-on-year growth at constant currency, raises net sales guidance for the full year. Manufacturer material
Clinical improvement was reported in this study (see original paper for details).

Risks & Side Effects

Swelling, bruising, tenderness, firmness, asymmetry, and overcorrection may occur. The most important risk is vascular compromise, especially near the mental artery, submental artery, and adjacent lower-lip branches. Superficial placement can create visible irregularity or palpability, and because this is a deep-support filler, detailed anatomy knowledge and hyaluronidase readiness are essential.

Interested in this treatment?

Start with an AI skin analysis to check your current skin condition

Get AI Skin AnalysisBook Now

Other Treatments

LaserPicoSure ProLearn more LaserFractional LaserLearn more LaserPhotofacial IPL (Stellar M22)Learn more Anti-AgingThermage FLXLearn more